| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | - | Sell | 60,213 | $1,034.78 | $62,306,968.56 | - | +0.6% | - | |
| Nov 18, 2025 | LQDA Liquidia Corp | Adair Jason | Chief Business Officer | Sell | 35,656 | $30.03 | $1,070,710.46 | -16.9% | +12.1% | - | |
| Nov 18, 2025 | PAHC Phibro Animal Health Corp | Bendheim Jack49 | President And CEO | Sell | 10,560 | $44.19 | $466,630.79 | -6.4% | +20.5% | - | |
| Nov 17, 2025 | UTHR United Therapeutics Corp | Edgemond James | CFO And Treasurer | Sell | 21,000 | $470.36 | $9,877,534.51 | -13.2% | +2.2% | - | |
| Nov 17, 2025 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 23,187 | $36.81 | $853,490.28 | -24.8% | -54.3% | - | |
| Nov 17, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Nark Ted C | Director | Sell | 50,000 | $11.72 | $586,000.00 | -14.7% | +31.2% | - | |
| Nov 17, 2025 | IRWD Ironwood Pharmaceuticals Inc | Gaskins Tammi L | Chief Commercial Officer | Sell | 6,016 | $3.32 | $19,973.12 | -2.5% | +52.7% | - | |
| Nov 17, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Tessari Eben | Chief Operating Officer | Sell | 12,470 | $41.24 | $514,224.10 | -17.9% | +9.6% | - | |
| Nov 17, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | - | Sell | 9,886 | $1,030.68 | $10,189,269.49 | - | +1.4% | - | |
| Nov 17, 2025 | PCRX Pacira Biosciences, Inc. | Slonin Jonathan72 | Chief Medical Officer | Sell | 3,960 | $24.09 | $95,396.40 | -2.2% | -4.8% | - | |
| Nov 17, 2025 | UTHR United Therapeutics Corp | Benkowitz Michael | President And COO | Sell | 22,500 | $470.43 | $10,584,756.00 | -100% | +2.2% | - | |
| Nov 17, 2025 | UTHR United Therapeutics Corp | Rothblatt Martine A | Chairperson &CEO | Sell | 8,000 | $465.25 | $3,721,966.55 | -47.5% | +2.2% | - | |
| Nov 14, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | - | Sell | 178,295 | $605.74 | $108,000,001.85 | - | +1.3% | - | |
| Nov 14, 2025 | TEVA Teva Pharmaceutical Industries Ltd | Fox Christine | EVP, Head Of U.s. Commercial | Sell | 30,000 | $25.11 | $753,321.00 | -51.4% | +33.5% | - | |
| Nov 13, 2025 | UTHR United Therapeutics Corp | Mahon Paul A | EVP &General Counsel | Sell | 11,000 | $464.76 | $5,112,335.17 | -2.5% | +2.9% | - | |
| Nov 13, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 16,679 | $26.49 | $441,836.72 | -18.1% | +8.4% | - | |
| Nov 13, 2025 | ANIP Ani Pharmaceuticals Inc | Walsh Patrick D52 | Director | Sell | 8,643 | $86.88 | $750,903.84 | -12.3% | -9.8% | - | |
| Nov 13, 2025 | LLY Eli Lilly & Co | Zakrowski Donald A | SVP, Finance, &CAO | Sell | 1,000 | $1,010.50 | $1,010,500.00 | -26.0% | -0.7% | - | |
| Nov 13, 2025 | ANIP Ani Pharmaceuticals Inc | Cook Meredith50 | Sr. VP, General Counsel &Sec. | Sell | 400 | $87.27 | $34,908.00 | -0.5% | -9.8% | - | |
| Nov 13, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | - | Sell | 46,606 | $1,030.26 | $48,016,098.38 | - | -0.7% | - | |
| Nov 13, 2025 | BCRX Biocryst Pharmaceuticals Inc | Sanders MacHelle45 | Director | Sell | 9,600 | $7.14 | $68,544.00 | -23.9% | -0.9% | - | |
| Nov 13, 2025 | ANIP Ani Pharmaceuticals Inc | Gassert Chad60 | SVP - Corp. Dev. &Strategy | Sell | 14,736 | $89.06 | $1,312,434.94 | -4.4% | -9.8% | - | |
| Nov 13, 2025 | UTHR United Therapeutics Corp | Rothblatt Martine A | Chairperson &CEO | Sell | 8,000 | $594.48 | $4,755,854.16 | -31.0% | +2.9% | - | |
| Nov 13, 2025 | PAHC Phibro Animal Health Corp | Bendheim Jack49 | President And CEO | Sell | 30,337 | $45.01 | $1,365,393.46 | -53.7% | +15.3% | - | |
| Nov 12, 2025 | OGN Organon & Co. | Cox Carrie Smith51 | Executive Chair | Buy | 65,400 | $7.67 | $501,755.34 | +524.5% | +1.3% | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.